Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A real-world study suggests GLP-1 medications like semaglutide and tirzepatide may offer a modest kidney-protective edge over finerenone in patients with type 2 diabetes and chronic kidney disease. The study found a 29% lower relative risk of progressing to advanced kidney disease with GLP-1 drugs, though the absolute difference was small and not statistically significant. The findings add nuance to how clinicians choose between these two guideline-recommended therapies.
When it comes to protecting kidneys in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), two widely used add-on therapies — GLP-1 receptor agonists and finerenone — have never gone head-to-head in a clinical trial. A new real-world study of over 4,500 patients is now offering some of the first comparative data, and GLP-1 drugs appear to have a slight edge.
Researchers analyzed data from a global health database, following patients with T2D and stage 3 or 4 CKD for up to 2.5 years. Those started on GLP-1-based drugs (including semaglutide, tirzepatide, dulaglutide, and liraglutide) showed a 29% lower relative risk of progressing to end-stage kidney disease, stage 5 CKD, or dialysis compared to those on finerenone. Kidney function also declined more slowly in the GLP-1 group — but that gap narrowed after the first six months. The benefit appeared strongest in patients with a BMI of 30 or higher, hinting that GLP-1 drugs' metabolic effects may play a role in kidney protection.
By the Numbers:
Why it matters: With no head-to-head trial yet available, clinicians often choose between GLP-1 drugs and finerenone based on cost, pill burden, and patient preference. This study suggests GLP-1 drugs may offer a modest kidney benefit — particularly in patients with obesity — but the small absolute difference means individualized decision-making remains key.
